ReviewJapanese journal of ophthalmology2018
Diagnosis and treatment of anti-myelin oligodendrocyte glycoprotein antibody positive optic neuritis.
Review in Japanese journal of ophthalmology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 42 citations in OpenAlex.
- Non-Contrast Fat-Saturated FLAIR MRI: Utility for Detecting Posterior and Seronegative-Associated Lesions in Optic Neuritis.Diagnostics (Basel, Switzerland) · 2026Article
- Neuroophthalmological evaluation in primary inflammatory demyelinating diseases with special reference to optic neuritis: A prospective study.Journal of family medicine and primary care · 2025Article
- Proteome-Wide Analysis of Autoantibodies in Open-Angle Glaucoma in Japanese Population: A Pilot Study.Biomedicines · 2025Article
- Pain and Headache in Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease.Current pain and headache reports · 2025Review
- Clinical features of adult patients with positive NMDAR-IgG coexisting with MOG-IgG.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2024Article
- Positive Myelin Oligodendrocyte Glycoprotein Antibodies in Isolated Optic Neuritis in a 14-Year-Old Child.Cureus · 2024Article
- Fast and accurate genome-wide predictions and structural modeling of protein-protein interactions using Galaxy.BMC bioinformatics · 2023Article
- Details and outcomes of a large cohort of MOG-IgG associated optic neuritis.Multiple sclerosis and related disorders · 2022Article
- Increased Plasma Lipocalin-2 Levels in Patients with Myelin Oligodendrocyte Glycoprotein-IgG-Positive Optic Neuritis.Journal of clinical medicine · 2022Article
- OCT retinal nerve fiber layer thickness differentiates acute optic neuritis from MOG antibody-associated disease and Multiple Sclerosis: RNFL thickening in acute optic neuritis from MOGAD vs MS.Multiple sclerosis and related disorders · 2022Article
- A Longitudinal Comparison of the Recovery Patterns of Optic Neuritis with MOG Antibody-Seropositive and AQP4 Antibody-Seropositive or -Seronegative for Both Antibodies.Journal of ophthalmology · 2022Article
- Risk of Autoimmune Diseases Following Optic Neuritis: A Nationwide Population-Based Cohort Study.Frontiers in medicine · 2022Article
- Current understanding of the epidemiologic and clinical characteristics of optic neuritis.Japanese journal of ophthalmology · 2021Review
- Recurrent Bilateral Optic Neuritis Associated with Myelin Oligodendrocyte Glycoprotein Antibody: A Case Report from Nepal.Case reports in neurological medicine · 2021Article
- Neurological update: MOG antibody disease.Journal of neurology · 2019Review
- Different Characteristics of Aquaporin-4 and Myelin Oligodendrocyte Glycoprotein Antibody-Seropositive Male Optic Neuritis in China.Journal of ophthalmology · 2019Article
- Pattern Visually Evoked Potentials in Japanese Girl With Optic Neuritis and Seropositive to Anti-myelin Oligodendrocyte Glycoprotein (MOG) Antibody.Frontiers in neurology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Anti-myelin-oligodendrocyte glycoprotein (MOG) antibody positive optic neuritis has been established as a new subset of optic neuropathy. Anti-MOG antibodies are usually measured by cell-based assay. Patients with anti-MOG antibody positive optic neuritis respond well to steroid therapy, and, while visual acuity outcomes are favorable, significant visual field defects remain. Furthermore, patients who are anti-MOG antibody positive have higher rates of recurrence compared to antibody negative patients. Based on these findings, anti-MOG antibody positive patients with optic neuritis have the characteristics of good visual outcomes, residual visual field defects, and high risk of recurrence. Tests for anti-MOG antibody are useful for the diagnosis and treatment of optic neuritis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.